Answers are grounded in this paper and cite their sources.
AIM: on visceral adiposity index (VAI) in obese patients. PATIENTS AND METHODS: 166 mg/day. The duration of the treatments was three consecutive months. Body mass index (BMI), VAI, blood pressure, blood glucose, total lipid profile, atherogenic index, and cardiac risk ratio were recorded at baseline and after 3 months. RESULTS: < 0.01 compared to pretreatment period. CONCLUSION: with orlistat lead to more significant effect than orlistat alone in amelioration of cardiometabolic profile and VAI in obese patients.
No takes yet. Share an insight, caveat, or question.
Al-Kuraishy et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: